Dermmedica Sp. z o.o.
- Address
- Ul. Krzysztofa Kolumba 6, 51-503 Wroclaw, Poland
Immune System Diseases
At Dermmedica Sp. z o.o. in Wroclaw, clinical research in this area focuses on immune-mediated conditions such as atopic dermatitis and hidradenitis suppurativa. These studies are designed to assess how well new treatments work over time and how well they are tolerated in people living with chronic inflammatory disease.
- Evaluating the long-term safety and tolerability of a therapy for atopic dermatitis
- Comparing a potential treatment with placebo in hidradenitis suppurativa
Overall, the site contributes to research aimed at improving symptom control, treatment durability, and patient quality of life in immune system diseases.
Skin and Connective Tissue Diseases
This research area centers on skin disorders, especially moderate to severe plaque psoriasis and atopic dermatitis. The trials at this hospital/clinic are exploring whether new therapies can better reduce disease activity and provide sustained benefit for patients with persistent dermatologic conditions.
- Testing the effectiveness of a new treatment for plaque psoriasis
- Assessing longer-term outcomes in atopic dermatitis
The work reflects a strong focus on advancing care for chronic skin and connective tissue diseases through improved treatment options and better disease management.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
- 1Almirall S.A.1active
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Almirall S.A.2trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Dermmedica Sp. z o.o.
lock Showing 1 of 7 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A 2-year Open-label Extension Study to Assess the Long-term Safety and Efficacy of Lebrikizumab in Adult and Adolescent Patients with Moderate-to-Severe Atopic Dermatitis | Almirall S.A. | Phase III | Not Recruiting | May 2023 | Apr 2026 |
IMP list
lock Showing 1 of 8 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Bimekizumab | 1 | Unknown | 2026-01-07 | 2026-01-07 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.